Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 43 | 0.91 |
| pathways Reactome | Reactome did not answer (Reactome: HTTP 429) | 0.00 |
No case: the score is under the bar. Receipt 10402
Sealed predictions
- MPZL2 in dopamine neurons, braak+0.63 (p 0.067) → +0.32 (p 0.407)receipt 10409
Swarm cases
receipt 10409: MPZL2 in dopamine neurons, braak
- power
- full sample +0.65 (p 0.0034, n 18), 95% CI +0.26 to +0.86. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.62 (p 0.0057, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.59 (p 0.011, n 18). not the mix.
- skeptic
- leave-one-out range +0.61 to +0.72, sign flips 0; without severely affected donors +0.65 (p 0.0034, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MPZL2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts